Literature DB >> 10604543

Tissue kallikrein and kinins in renal disease.

S Naicker1, S Naidoo, R Ramsaroop, D Moodley, K Bhoola.   

Abstract

The renal kallikrein-kinin system is involved in sodium and water homeostasis, blood pressure regulation and inflammation. Tissue kallikrein and kinin levels were measured in the urine of patients with renal disease and in the urine of living related kidney donors prior to uninephrectomy who served as controls. Tissue kallikrein and kinin B1 and B2 receptors were immunolocalised by confocal microscopy in renal biopsy material from patients with renal disease and controls (fresh autopsy material and normal kidney tissue from nephrectomies for malignancy). Urinary tissue kallikrein excretion was significantly decreased in patients with mild renal disease (16.6 +/- 6.7 ng tissue kallikrein (TK)/ng protein; p < 0.05) and more markedly so (1.8 +/- 0.7 ng TK/microg protein; p < 0.01) in patients with severe renal failure requiring dialysis compared to normal controls (78.9 +/- 31.7 ng TK/microg protein). Basal kinin values were unchanged in patients with renal disease (14 +/- 0.8 ng/ml) compared to controls (13.3 +/- 0.56 ng/ml). In control kidney tissue kallikrein was immunolocalised in the distal connecting tubules and collecting ducts whereas decreased immunolabelling was observed with renal disease. Kinin B2 receptor labelling was present in the entire nephron in the normal control kidney but was reduced with renal disease. While kinin B1 receptor immunolabelling was not observed in the control kidneys, labelling of distal tubules and collecting ducts was noted in renal disease, suggesting an upregulation of B1 receptors in renal parenchymal disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10604543     DOI: 10.1016/s0162-3109(99)00089-2

Source DB:  PubMed          Journal:  Immunopharmacology        ISSN: 0162-3109


  8 in total

1.  Leukocytic cell sources of airway tissue kallikrein.

Authors:  Isabel T Lauredo; Rosanna M Forteza; Yelena Botvinnikova; William M Abraham
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2003-12-05       Impact factor: 5.464

Review 2.  Kallikrein-kinin in stem cell therapy.

Authors:  Julie Chao; Grant Bledsoe; Lee Chao
Journal:  World J Stem Cells       Date:  2014-09-26       Impact factor: 5.326

Review 3.  The role of the renal kallikrein-kinin system in diabetic nephropathy.

Authors:  Alexander Riad; Jia Long Zhuo; Heinz Peter Schultheiss; Carsten Tschöpe
Journal:  Curr Opin Nephrol Hypertens       Date:  2007-01       Impact factor: 2.894

4.  Kinin B2 receptor does not exert renoprotective effects on mice with glycerol-induced rhabdomyolysis.

Authors:  Pedro Paulo Gattai; Fernando Francisco Pazello Mafra; Frederick Wasinski; Sandro Soares Almeida; Marcos Antônio Cenedeze; Denise Maria Avancini Costa Malheiros; Reury Frank Pereira Bacurau; Carlos Castilho Barros; Niels Olsen Saraiva Câmara; Ronaldo Carvalho Araujo
Journal:  World J Nephrol       Date:  2014-08-06

Review 5.  Genetically‑modified stem cells in treatment of human diseases: Tissue kallikrein (KLK1)‑based targeted therapy (Review).

Authors:  Marina Devetzi; Maria Goulielmaki; Nicolas Khoury; Demetrios A Spandidos; Georgia Sotiropoulou; Ioannis Christodoulou; Vassilis Zoumpourlis
Journal:  Int J Mol Med       Date:  2018-01-03       Impact factor: 4.101

6.  Diabetes-induced upregulation of kallistatin levels exacerbates diabetic nephropathy via RAS activation.

Authors:  Yanhui Yang; Xuemin He; Rui Cheng; Qian Chen; Chunyan Shan; Liming Chen; Jian-Xing Ma
Journal:  FASEB J       Date:  2020-04-30       Impact factor: 5.191

Review 7.  Human tissue kallikrein in the treatment of acute ischemic stroke.

Authors:  Michelle Alexander-Curtis; Rick Pauls; Julie Chao; John J Volpi; Philip M Bath; Todd A Verdoorn
Journal:  Ther Adv Neurol Disord       Date:  2019-01-20       Impact factor: 6.570

Review 8.  Function and structure of bradykinin receptor 2 for drug discovery.

Authors:  Jin-Kang Shen; Hai-Tao Zhang
Journal:  Acta Pharmacol Sin       Date:  2022-09-08       Impact factor: 7.169

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.